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ABSTRACT 
One of the major challenges of bone tissue engineering is the production of a 
suitable scaffold material. In this review the current composite materials options 
available are considered covering both the methods of both production and 
assessing the scaffolds. A range of production routes have been investigated 
ranging from the use of porogens to produce the porosity through to controlled 
deposition methods. The testing regimes have included mechanical testing of the 
materials produced through to in vivo testing of the scaffolds. While the ideal 
scaffold material has not yet been produced, progress is being made.  
 
Keywords:  Bioactive, biodegradable, biomechanical properties, composites, 
porosity, tissue engineering scaffold 
 
INTRODUCTION 
The requirements for scaffold materials for bone 
tissue engineering are easily defined however our 
ability to produce such materials is limited. The 
scaffold needs to contain both macropores, 300-
400µm across, to allow osteons or bone spicules 
to grow into the scaffold [1] and micropores to 
encourage nutrient supply and the removal of 
waste products [2,3]. The material needs to be 
bone bioactive, that is to encourage bone 
ingrowth, and to degrade, at an appropriate rate, to 
allow the newly formed tissue gradually to replace 
the scaffold, both as mechanical structure and in 
terms of space occupied. Finally, and this is where 
most current materials fail, the material needs 
mechanical properties that allow the device to be 
implanted without failing thus allowing the 
patient to use the implanted area without 
mechanical protection such as a cast but also to 
allow sufficient loading of the newly formed 
tissue to stimulate mechanically the osteoblasts. 
As yet no one has reported a material that fulfils 
all these requirements.  
However, one group of materials that do attempt 
fulfil many of these requirements are composites 
of degradable polymers reinforced with ceramics, 
glass-ceramics or bioglasses. If the polymer is 
biodegradable and the ceramic, glass-ceramic or 
bioglass phase is degradable or metabolised by the 
body then the degradation requirement is fulfilled. 
The use of ceramics or glass-ceramics can both 
stiffen and strengthen a low modulus and lwo 
strength polymer and increase the bioactivity of 
the composite [4]. Finally a range of techniques 
can be used to develop a porous structure, 
including porogens that are processed into the 
material and then develop the required porosity 
either by generating gas bubbles or by being 
dissolved out and leaving spaces. Other methods 
of generating porosity include depositing the 
material with gaps between individual material 
fibres such as electrospinning and fused laser 
deposition.  
This review will consider only composite 
scaffolds, as the use of composites allows the 
combination of bioactive ceramics or glasses, 
which are stiff and bioactive, but normally are too 
brittle for load bearing applications, with 
polymers which are ductile but do not have 
sufficient stiffness or biological activity, for 
mechanically successful bone implantation. These 
composite scaffolds can be produced by a variety 
of methods including manufacturing a composite 
material in a porous form, taking a brittle ceramic 
scaffold and toughening it by coating with a 
polymer or taking a tough polymeric scaffold and 
coating it with a bioactive layer, using a technique 
such as soaking in supersaturated simulated body 
fluid (SBF) or calcium and phosphate containing 
solutions. The most commonly used SBF is SBF-
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K9 developed by Kokubo et al. [5] to test the 
relative bone bioactivity of ceramics and glass 
ceramics. SBF-K9 has very similar ionic 
concentrations to blood plasma, but no protein 
content, the rate at which it deposits on a bone 
bioactive material usually is considered to be 
indicative of the rate of incorporation in the body 
in vivo and deposition does not occur on non-bone 
bioactive materials [6]. If, however, the SBF 
strength is increased then an hydrated carbonate 
apatite (HCA) layer can be deposited on a bioinert 
surface rendering it bioactive [7].  The artificial 
polymers used include the polylactic acid (PLA), 
polyglycolic acid (PGA) and polyhydroxybuterate 
(PHB) and various of their co-polymers and 
polymer blends. From natural sources there are 
two major polymers, collagen, the main 
connective tissue of the body, while chitosan, 
purified from the shells of prawns and other 
shellfish is a by-product of the food industry. 
Collagen used as a biomaterial is usually purified 
from bovine tendon, although bone and dentine 
are other potential sources [8]. Chitosan is 
biodegradable and the mechanical properties can 
be altered by the degree of acetylation, 
furthermore it can absorb and release various 
cytokines and other bioactive molecules, thus 
changing the biological response to the implanted 
material [9,10]. The fillers used include tricalcium 
phosphate (Ca3(PO4)2 – TCP), a degradable 
calcium phosphate related to hydroxyapatite 
(Ca10(PO4)6(OH)2 – HA), which in turn is the 
stiochoimetric version of bone mineral, bioglasses 
of various types such as Bioglass® 45S5 and 
other glass ceramics including A-W glass 
ceramic. When considering ceramic-polymer 
composite formulation the factor of typically three 
difference in the density of the ceramic and the 
polymer phases leads to major differences in the 
filler content when defined as weight percentage 
or volume percentage.  
This review will consider the methods of 
producing the required porosity and the materials 
used. The testing  regimes from in vitro 
bioactivity, to in vitro cell culture and finally in 
vivo testing will be reviewed.  
 
POROGEN MANUFACTURED SCAFFOLDS 
Porogens, or substances that produce porosity, are 
available in three basic types, those that dissolve, 
those that melt and those that produce gas 
bubbles. The two most commonly used soluble 
porogens are sugar and salt, both of which are 
available in a variety of sizes to produce a suitable 
range of pore sizes and are easily dissolved in 
water. Furthermore the products are not cytotoxic, 
except in very high doses, so any remaining 
porogen after dissolution which subsequently 
leaches out in vivo, will not generate a cytotoxic 
response. The second group are the waxes which 
are removed by melting, these have been used less 
often, probably due to concerns over any wax 
remaining in a closed cell. Some carbon dioxide 
producing chemical reactions based porous 
scaffolds have been produced. Porogens have 
been used to manufacture PLA, PGA and PHB 
based scaffolds. 
 
Polylactic acid scaffolds produced using porogens  
Charles-Harris et al., [11,12] produced porous 
PLDLA reinforced with 20 or 50wt% calcium 
phosphate glass scaffolds by solution casting 
using sodium chloride salt particles to produce 
porosity. After dissolving the PLDLA in 
chloroform the P2O5-CaO-Na2O-TiO2 based glass 
and salt were added and the chloroform was 
allowed to evaporate and then the salt dissolved 
out. They found increased protein absorption with 
increasing glass content. They subsequently 
cultured cells from the MG63 osteoblast cell line 
on the scaffolds in both static and dynamic 
(perfusion) environments [13].  They found 
increases in cell proliferation and differentiation 
on the glass containing composite than the plain 
PLDLA. They found that the perfusion regime 
increased the cell seeding efficiency and produced 
more even cell distribution. For 95% porous 
scaffolds they were able to obtain scaffold 
stiffnesses up to 217kPa by optimising the size of 
the glass and salt particles. They do comment that 
at this level of porosity the glass filler particles do 
not act to stiffen or strengthen the polymer but 
rather act as defects due to the lack of bonding 
between the polymer and the glass particles. The 
smooth surfaces of glass particles commonly 
leads to a low strength interface between the filler 
and matrix and thus low mechanical properties 
[14]. While chemical coupling agents have been 
used in non-degradable composites [15] their use 
in degradable composites such as tissue scaffolds 
leads to additional concerns involving their 
degradation products.  
Some researchers have relied on the natural 
structure of coral to provide required macro and 
micro pore size and shape for bone scaffold 
materials. Kusmanto et al. [16] used a naturally 
porous red coralline alga, Phymatolithon 
calcareum, with mean pore size of 7µm to 
produce the required macropores. Pyrolysis was 
used to convert the coral to CaO and then to 
CaCO3 and finally hydrothermal conversion was 
used to transform the material to microporous HA 
which was mixed with PCL to produce the 
composite. Salt particles were used as the porogen 
to produce macropores. SEM showed that the HA 
particles retained the microporosity of the alga 
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precurser and that the macroporosity depended on 
the size of the salt particles. For a given porosity 
level the stiffness and strength were higher when 
larger salt particles were used, that is the pore size 
was increased. Cell culture showed the materials 
to be biocompatible with cells from the MG63 
osteoblast-like cell line able to interact with the 
micropores in the HA phase (Figure 1).  
 
Polylactic acid-glycolic acid scaffolds produced 
using porogens 
Kim et al. [17] compared composite scaffolds of 
PLGA reinforced with HA made using gas 
foaming and porogen leaching with those made 
using the more conventional solvent casting and 
porogen leaching. The solvent casting-porogen 
leaching samples had open cells 100-200µm in 
diameter while gas foaming lead to both open 
cells of similar size produced by the dissolution of 
the salt particles and closed cells 10-45µm in 
diameter, which thus increased the average 
porosity from 85 to 91%. However, the gas 
foamed samples had twice the compressive 
modulus and 13 times the tensile modulus to the 
solution cast scaffolds. Cell culture studies, using 
rat calveria osteoblasts, showed that the addition 
of the HA increased the cell number and 
calcification from unfilled solvent case PLGA and 
yet higher activity was found on the gas foamed 
samples. When implanted subcutaneously in nude 
mice a similar trend was seen to the in vitro cells 
culture studies.  
 
Guarino and Ambrosio [18] used filament 
winding to produce scaffolds of drawn PLA fibres 
in a matrix of PCL reinforced with up to 26vol% 
α-TCP using salt particles to produce porosity. 
The PLA fibres were drawn through a solution of 
PCL in dimethylacetamide with α-TCP and salt 
particles 300-500µm in diameter suspended in the 
solution. The coated PLA fibres were then 
filament wound to produce the material and 
soaked in water for 24 hours to leach out the salt 
particles. This production method lead to tubular 
specimens of 3mm internal diameter, 7mm 
external diameter with 80% porosity consisting of 
macropores 100-400µm in diameter connected by 
micropores. 
The addition of the α-TCP increased the modulus 
from 0.49±0.04 MPa to 2.21±0.24MPa in the 
initial linear region of the stress-strain curve and 
the material behaved as a typical foam, gradually 
compacting as the load increased.  
 
Other porogen produced scaffolds 
Li and colleagues [19, 20] manufactured scaffolds 
of PHBV reinforced with up to 20wt% of a 
bioglass or wollastonite glass also using salt 
leaching to generate the requisite porosity. For 
porosities of 77 to 80%, the addition of the 
bioglass increased the yield strength from 
0.16±0.03 to 0.41±0.09MPa. Pore sizes were 
between 30 and 300 µm. Soaking in SBF showed 
the 20wt% bioglass composite to be potentially 
bioactive, although the water contact angle 
decreased with increasing bioglass content. The 
pH of the solution remained constant for the first 
8 days when there was no reinforcing phase and 
 
  
 
Figure 1 MG63 osteogenic cells seeded at 5,000 cells and cultured for 5 days on a coral based HA (marker 
bars = 10µm ) (from Kusmanto et al. [15]) 
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then decreased with a major drop seen after 8 
weeks, whereas with the filled composites the pH 
of the solution initially increased slightly and then 
remained constant. The addition of the filler 
particles also reduced the degradation as 
measured by the molecular weight of the polymer 
phase.  
Oliveria et al. [21] used co-precipitation to 
produce composites of carboxymethylchitosan 
reinforced with 24 vol% HA. Wax spheres 50-450 
µm in diameter were incorporated to produce the 
required porosity and the wax was subsequently 
removed by soaking the scaffolds in 
tetrahydrofuran which was then removed by 
freeze drying. Open celled pores 20-500µm across 
were produced with specimen porosity of nearly 
60% and the scaffolds were shown to be bone 
bioactive by being coated with an apatitic layer 
after soaking in SBF. The compressive stiffness 
and strength were 57.3 and 51.0 MPa 
respectively.  
 
POROUS MANUFACTURE 
The two most commonly used methods of direct 
porous manufacture are supercritical processing 
and freeze-drying directly from a suspension, with 
newer techniques such as fused deposition and 
electrostatic spraying becoming more popular. 
The group at the National University of Singapore 
have used fused deposition modelling to 
manufacture scaffolds of PCL reinforced with 
20% TCP and subjected these scaffolds to a series 
of studies [22-24]. The scaffolds are laid down 
with a 0˚/60˚/120˚ pattern that produces 
hexagonal channels 600µm across through the 
scaffolds (Figure 2). They investigated the 
degradation of the scaffolds and show that they 
would survive at least 28 days with changes in the 
pH of the solution only appearing after 20 days. 
They have shown these scaffolds to capable of 
releasing BMP-2 and thus upregulating 
osteoblasts during the first few postoperative 
days.  
Chen and Boccaccini [25] developed scaffolds of 
Bioglass® 45S5 reinforced with poly(3-
hydroxybutyrate) (PHB) by using a slurry of 
Bioglass® 45S5 to coat polyurethane (PU) foams 
with either 45 or 60 pores per inch (25mm). After 
sintering the structure consisted of rods of 
Bioglass® and these scaffolds were then 
immersed in a solution of PHB in chloroform. 
After drying the presence of the PHB coating 
reduced the surface tension. They showed the 
bioactivity of the scaffolds by the development of 
an apatitic coating after soaking in SBF for up to 
28 days. Finally cells from the HOS-TE85 
osteoblast cell line were grown on the scaffolds 
and showed similar responses to coated and 
uncoated specimens although the cells did appear 
to attach better to the PHB coated specimens [26].  
 
 
 
Figure 2 Fused deposition scaffold of PCL-TCP produced by Rai et al. [21] showing the size of the channels 
produced through the scaffold. Scale bar = 500µm. (from Rai et al [21]) 
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Liao and Cui and colleagues [27-29] 
manufactured a composite of nanoHA in type I 
collagen, they then used this material to reinforce 
PLLA with the porosity generated by a freeze 
drying process. The pores were 100-300µm across 
and the compressive strength was between 13 and 
1.9MPa for 8 to 12% PLLA content, with the 
compressive modulus between 20 and 45MPa. 
Both in vitro and in vivo testing showed the 
material to be biocompatible and bioactive. One 
method of increasing the mechanical properties is 
to add reinforcement in the form of fibres or to 
cross-link the polymeric phase, thus Li et al. [30] 
took their colleagues’s material and added 
chitosan fibres which in some cases they cross-
linked. Increasing the chitosan fibre content from 
10 to 50vol% lead to a reduction in porosity from 
91 to 83% and the mean pore size from 190±5µm 
to 140±5µm. Adding chitosan fibres without any 
cross-linking increased the modulus from 
1.71MPa to 4.1MPa at 22vol% content, but when 
the fibres were cross-linked the modulus reached 
8.36MPa. Adding the chitosan fibres increased the 
hydrophilicity of the PLLA/nanoHA/collagen 
composite and thus attachment of bone marrow 
derived mesenchymal cells with neglible 
mechanical effects produced by the cross-linking.  
Catledge et al. [31] used electrospinning to 
produce scaffolds of PCL, collagen and PCL-
collagen all reinforced with 20 wt% 
nanohydroxyapatite. All three composites 
produced porous scaffolds and nanoindentation 
after compaction showed that the highest Young’s 
modulus for the fibres was found for the collagen-
nanoHA scaffold followed by the PCL-collagen-
nanoHA. 
 
Heo et al. [32,33] produced nanosized HA and 
mixed it into a solution of PLA and then used a 
rapid prototyping system to build up scaffolds of 
rods of the composite about 300µm in diameter 
separated by about 500µm, with each layer 
deposited at right angles to the underlying layer in 
a layer manufacturing process (Figure 3). Micron 
sized HA based scaffolds were used as controls 
and the porosity of both scaffolds was 72-73%. 
Compression testing showed more effective 
reinforcement by the nanoHA particles as the 
modulus was 3.2±0.1MPa versus 1.3±0.1MPa for 
the macroHA reinforced composite. Contact angle 
measurements showed the nanoHA reinforced 
scaffolds to have faster water absorption which 
correlated with higher MG63 osteoblast cell line 
attachment from 4 hours to 7 days. SEM showed 
that the scaffolds produced with the nanoHA were 
much smoother allowing the cells to spread more 
extensively. Mesenchymal stem cells were also 
cultured on both these scaffolds and also 
proliferated and differentiated more on the 
nanoHA reinforced scaffolds. The nanoHA 
reinforced scaffolds were then implanted into 
critical size defects in rabbit tibiae with nanoHA 
reinforced scaffolds produced by a more 
conventional porogen based technique, but with 
similar porosity, as controls. There was more, and 
more organised, osteoid deposition in the layer 
manufactured scaffolds than those produced using 
the porogen technique. Hong et al. [34] used a 
similar technique to produce 50wt% HA in PCL 
scaffolds and showed similar cell viability for rat 
bone marrow stromal cells, but with increased cell 
differentiation for the HA-PCL scaffolds than the 
non-reinforced PCL scaffolds.  
 
Figure 3 Layer manufactured nanoHA reinforced PLA scaffold produced by Heo et al. [31] showing the pore 
size to be approximately 500µm and the smooth surface of the material. Marker bar = 300µm. (reproduced 
from Heo et al. [31]) 
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Costa et al. [35,36] foamed polyvinyl alcohol 
(PVA) reinforced with 20 to 40wt% of 58%SiO2-
33%CaO-9%P2O5 to produce porous scaffolds. 
After morphological, chemical and 
mechanicacharacterisation the scaffolds were 
cultured with cells from the VERO line. At 
30wt% glass the effect of increasing the molecular 
weight of the PVA from 9,000-10,000 to 13,000-
23,000 g mol-1 was to increase the stiffness of the 
scaffold from 2.6 to 5.9 MPa, although there was 
minimal change in the strength, while they 
comment that the glass alone did not have 
sufficient mechanical properties to be handled, let 
alone tested. The cell culture studies showed good 
cell viability on the composite scaffolds.  
Duarte et al. [37] used supercritical processing to 
produce porous scaffolds of starch-polylactic acid 
blend reinforced with 0, 10 or 15wt% Bioglass® 
45S5. Dynamic mechanical analysis (DMA) was 
used to measure the compressive mechanical 
properties of the scaffolds and showed that the 
addition of the Bioglass® increased the dynamic 
stiffness. Soaking in SBF showed the composites 
to have higher bone bioactivity than the non-filled 
polymer.  
Liu and colleagues [38,39] used PLLA, PLDLA 
and PGA all reinforced with 30 or 50wt% TCP 
and then used a combination of low temperature 
deposition to produce macropores or channels 
through the materials and freeze drying to produce 
micropores. In a series of purely mechanical tests 
 
they optimised the production route. 30wt% TCP 
gave a stronger material than 50wt% TCP for 
each polymer and using PLLA as the matrix 
materials lead to the highest mechanical 
properties at each filler level. They subsequently 
used a multi-nozzle system to co-deposit PLGA 
reinforced with 25wt% TCP with collagen or 
chitosan or gelatin to produce biphasic scaffolds. 
One such scaffold included blood vessel scaffolds 
laid down through the bone scaffold (Figure 4).  
Zhang and Zhang [9] used both β-TCP and a 
CaO-P2O5-TiO2-Na2O glass to reinforce chitosan 
and then freeze drying to generate porosity. 
Porosities between 75% and 90% were achieved 
with compressive moduli between 1 and 3MPa 
and strengths between 0.1 and 0.3MPa. Soaking 
in SBF showed the materials to be bioactive.  
 
CERAMIC DEPOSITION ON TO 
POLYMERS 
A bioceramic layer deposited onto a scaffold can 
be produced by soaking the polymeric scaffold in 
above physiological strength Simulated Body 
Fluid (SBF). If the strength of the SBF solution is 
increased then the rate of deposition is 
substantially increased and deposition will occur 
on many non-bioactive materials including porous 
polymer scaffolds rendering them bioactive. In 
addition pre-treatment with acid or alkaline 
solutions may generate apatite nuclei and thus all 
the deposition on non-bioactive surfaces [6]. 
 
  
Figure 4 Comparison of the healing after 12 weeks of a skull defect in a rabbit a) & c) with no implant in the 
defect and b) & d) with Gelatin/nano HAP/fibrin scaffold with rhBMP-2 in the defect (magnifications a) & 
c) 6× b) & d) 100×) (from Liu et al. [38]) 
a b 
c d 
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Al-Munajjed and colleagues [40,41] used freeze 
drying from a suspension of collagen to produce a 
90% porous collagen scaffold which they then 
alternately immersed in between 0.1 and 1.0M 
strength solutions of calcium chloride (CaCl2) and 
ammonium sodium hydrogen phosphate 
(NaNH4HPO4) to produce a calcium phosphate 
coating. They optimised the solution 
concentrations, soaking times and number of 
immersions and their order and increased the 
modulus from 0.27 to 10.3kPa. The coating was 
shown to be mainly HA with some small amounts 
of other calcium phosphates. In the second study, 
they soaked collagen scaffolds for 4 days in SBF 
at 5 times physiological strength (5SBF) to coat a 
99.5% porous collagen scaffold. The coating 
process increased the strength from 0.23kPa to 
0.9kPa and mouse MC3T3-E1 pre-osteoblast cells 
grown on the scaffolds showed minimal 
differences in their responses to the coated or non-
coated scaffolds. 
Douglas et al. [42] produced PLGA scaffolds by a 
salt leaching process and then soaked the 
scaffolds in triple strength SBF to produce an 
apatite coating. No mechanical tests were 
performed, but cell culture with human 
osteoblasts showed the scaffolds to be 
biocompatible.  
Jie and Li [43] precipitated nanoHA into PA66 
polyamide (nylon) by dissolving Ca(NO3)2 with 
the polyamide using an organic solvent and then 
reacting this solution with Na3PO4. After cleaning 
the composite scaffold was produced using an 
injection foaming method. The nanoHA content 
was between 39 and 64 wt% and as the nanoHA 
content increased the elastic modulus increased 
from 3.6±0.3GPa to 5.6±0.3GPa and the 
compressive strength from 93±7MPa to 
117±4MPa. XRD, TEM and infrared spectroscopy 
showed the mineral phase to be nanoparticles of 
HA. Increasing the nanoHA content, while it 
increased the porosity from 71 to 80%, also 
changed the closed cell and open cell macropore 
content from 9% and 91% respectively to 19% 
and 81% respectively, although they do point out 
that the closed cells were also interconnected by 
micropores. In subsequent studies they used 
thermally induced phase separation to produce the 
porosity and were able to obtain anisotropic pores, 
leading to up to a factor of two difference in the 
longitudinal and transverse compressive moduli 
and strengths and a maximum strength of 550MPa 
[44]. However, it seems unlikely that this material 
will be degradable.  
Mavis et al. [45] used electrospinning to produce 
a mat of nanosized PCL fibres and then soaked 
this in four of their own recipe 10 times strength 
SBFs for between 2 and 15 hours (Figure 5). The 
deposited particles were found to have Ca:P ratios 
between 1.3 and 1.5 and were therefore thought to 
be TCP or other various low calcium content 
CaPs which are expected to degrade fast on 
implantation. Culture with the MC3T3-E1 cell 
line showed that the materials were biocompatible 
and indeed bioactive with the cell activity 
increased on the coated scaffolds compare to 
uncoated control scaffolds.  
Oyane et al. [46,47] took plain PCL laid down in 
0˚/60˚/120˚ pattern to give a hexagonal scaffold 
by the group from National University of 
Singapore, then used either NaOH to produce 
carboxylate groups on the surface followed by 
alternate CaCl2 and K2HPO4 aqueous solutions or 
oxygen plasma treatment followed by soaking in 
the same calcium and phosphate salts by dissolved 
in either water or an ethanol:water mix. Their 
dipping times were much shorter than the other 
studies at 10 seconds per dip and only three dips 
per solution. The NaOH pre-treatment was found 
to need 2 or 5 M strength solutions to pre- 
condition the surface to allow formation of an 
 
 
Figure 5 Deposition of apatite crystals on 
electrospun PCL fibres after soaking in a 
simulated body fluid for a) 2 and b) 6 hours 
(marker bars = 2µm) (from Mavis et al. [44]) 
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apatite layer after 24 hours in SBF. The oxygen 
plasma treatment decreased the contact angle, as 
did the use of ethanol in the solution and with 
both oxygen plasma treatment and using an 
ethanol containing solution at 0.2 M strength 
solutions, they were able to modify the surface 
such that after 24 hours in SBF the surface was 
totally covered in apatite.  
A different approach was taken by Davies et al. 
[48] as they used a modified SBF to deposit an 
apatitic layer on poly(lactide-co-glycolide) 
microspheres and manufactured these into 
scaffolds using both the generation of CO2 gas 
and the use of salt particles as to produce porosity. 
The layer of apatite deposited on the polymer 
microspheres was used to incorporate a mineral 
phase in the material used to manufacture the 
scaffolds. They used human mesenchymal stem 
cells to assess the biocompatibility. The scaffolds 
were found to be osteoconductive, that is bone 
would grow over the surface if the material was 
implanted in contact with bone.  
PHB with 8mol% PHV was manufactured into 
porous scaffolds using salt as a porogen by Huang 
et al. [49]. After the salt was leached out and the 
samples dried, they were soaked in Ca(OH)2 
solution for one week, to produce apatite 
nucleation sites, and then in alternating solutions. 
After seven cycles of soaking in 100mM CaCl2 in 
Tris for 24 hours followed by 100mM Na2HPO4 
in Tris for 24 hours, with the samples washed 
between each solution. SEM and XRD showed 
that nanoparticles of apatite had been deposited in 
a continuous layer over the surface.  
A similar pair of solutions was used by Matsusaki 
et al. [50] who produced a scaffold of 
extracellular matrix including mesenchymal stem 
cells and then soaked this alternately in CaCl2 in 
50mM Tris-HCl buffer and in Na2HPO4 in 50mM 
Tris-HCl buffer for 10 seconds each with a 10s 
wash in plain 50mM Tris-HCl buffer between 
each active solution. The strengths of each of the 
CaCl2 and Na2HPO4 solutions was varied between 
10 and 200mM and either 10 or 20 soak cycles 
were used. The scaffolds were characterised by 
FTIR and live/dead staining of the cells that went 
through the alternating soak cycles. At 10 and 
50mM strength the number of live cells was not 
statistically reduced, but above these strengths 
there was a decrease in the number of live cells.  
 
POLYMER DEPOSITION ON TO 
CERAMICS 
Kim et al. [48] coated scaffolds of HA with an 
HA/PCL composite doped with tetracycline 
hydrochloride antibiotic as a drug delivery 
system. The HA scaffold was dip coated with 
between 20 and 80wt% HA in PCL. The 
compressive stiffness and strength increased from 
0.79±0.04MPa to 1.43±0.2MPa and from 
0.16±0.04MPa to 0.45±0.04 MPa respectively 
when the maximum amount of 50wt% HA coating 
was applied. Initially the drug release was fast and 
then slowed, but continued up to 7 days.  
Abarrategi et al. [49] deposited chitosan onto β-
TCP discs. The discs were produced by mixing β-
TCP, calcium phosphate and calcium carbonate 
with a solution of acetic acid. Pores were 
generated by the calcium carbonate-acetic acid 
interaction which produced CO2. Once the discs 
had set, been sterilised, washed in medium and 
dried they were either coated with chitosan 
containing recombinant human bone morphogenic 
protein-2 (rhBMP-2) or allowed to absorb the 
rhBMP-2 directly into their surfaces. The 
manufacturing process produced discs that were 
just over 50% porous and the porosity was 
reduced to approximately 47% by the chitosan 
coating although the process did alter the 
distribution of pore sizes. The production process 
gradually increased the strength from the “green” 
discs to the sterilised and washed discs at 
8.30MPa and after chitosan coating to 11.28MPa. 
After cell culture the devices were implanted 
8mm diameter defects in the skulls of rabbit. The 
discs coated in plain chitosan and those with 
absorbed rhBMP-2 but no chitosan produced 
“good bone response” after 3 weeks, but those 
coated with chitosan containing rhBMP-2 were 
totally covered with new bone.  
Cao et al. [50] used sol-gel processing to produce 
porous A-W glass-ceramic porous scaffolds and 
then coated these with chitosan. The chitosan 
coating increased the strength by a factor of over 
8, bringing the strength into the range for 
cancellous bone, but reduced the bone bioactivity 
as measured using soaking in SBF, however 
osteoblast cell adhesion was still good.  
Mantos et al. [51] used a polyurethane model to 
produce porous scaffolds of 50%SiO2-22.6%CaO-
5.9%Na2O-4%P2O5-12%K2O-5.3%MgO-
0.2%B2O3 glass and then dip coated these in 
PLDLA to produce a 1-5µm thick layer . The 
coating covered all the struts of the scaffold and 
increased the strength from 0.4MPa to 0.6MPa. 
The porosity ranged from 61% to 73% with the 
average pore size between 250m to 300µm, 
soaking in SBF for only 3 days lead to the 
production of an HCA layer on the scaffolds.  
 
CHARACTERISATION OF THE 
SCAFFOLDS 
Georgiou et al. [52] manufactured scaffolds of 
PLA reinforced with 46%CaO-4%Na2O-50%P2O5 
glass, with the porosity produced using 
supercritical CO2. DMA testing showed the 
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storage modulus of the solid material was 
increased from 4.4 to 5.2GPa by the addition of 
20wt% glass. However, the material and material 
porosity were inhomogeneous at this filler level. 
The ion release rate depended on the glass 
content. Culturing of human fetal bone cells 
showed the material to be biocompatible.  
Gelsinsky et al. [53] manufactured porous 
scaffolds of collagen type I reinforced by HA and 
then generated porosity using a freeze-drying 
process. Their production technique [54] resulted 
in the simultaneous reassembly of the collagen 
fibrils and precipitation of nanoparticles of HA. 
After the freeze drying process the scaffolds were 
cross-linked. The pores produced were 
approximately 200µm in diameter and 
thermogravimetric measurement showed the 
composite to be approximately 66 wt% HA. FTIR 
confirmed the presence of collagen type I and HA 
and micro CT showed the porosity to be about 
72% with a mean pore diameter of 180±12µm. 
The compressive strength when swollen in water 
was 14MPa at 20% strain and 23.5MPa at 40% 
strain. After 14 days culture viable human marrow 
stromal cells were found throughout the scaffold 
although there were more at the edges than in the 
centre.  
 
IN VITRO TESTING OF SCAFFOLDS 
Haimi et al. [55] cultured human adipose stem 
cells on PLA reinforced with between 0 and 20 
wt% of either β-TCP or a bioactive glass based on 
5%Na2O-7.5%K2O-3%MgO-25%CaO-
59.5%SiO2 with porosity produced by freeze 
drying. After 2 weeks, compared to non-
reinforced PLA scaffolds, statistically more cells 
were seen on the scaffolds reinforced with β-TCP 
and statistically less on the scaffolds reinforced 
with the bioactive glass. Higher alkaline 
phosphatase activity was seen on the β-TCP 
reinforced scaffolds after both 1 and 2 weeks, 
with no difference between the non-reinforced 
PLA scaffold and that reinforced with the 
bioactive glass.  
 
IN VITRO CELL SEEDING ONTO 
COMPOSITE SCAFFOLDS 
Blaker et al. [56] and Maquet et al. [57] used 
freeze drying to produce porosity in a composite 
of PDLLA reinforced with Bioglass® 45S5 with a 
mean particle size of >5µm, at either 5 or 40wt% 
Bioglass®. Cell culture was performed using the 
human osteosarcoma cell line MG-63. The mean 
macropore size was 100µm interconnected via 
micropores of 10-50µm, with scaffold anisotropy. 
Soaking in physiological strength SBF showed the 
materials to be bioactive in vitro. Surprisingly the 
 
cell culture showed similar numbers of osteoblasts 
in the scaffolds for scaffolds containing either 5 or 
40wt% Bioglass® although in both these cases 
this was more than on the plain PDLLA scaffolds.  
Cai et al. [57] used a combination of alginate and 
gelatine reinforced with TCP to produce scaffolds. 
They varied the degree of oxidation of the 
alginate to change the properties but found that 
neonatal rat calvaria osteoblasts were able to grow 
on the materials. Furthermore they showed that 
the material could be used for drug release.  
 
IN VIVO TESTING OF SCAFFOLDS 
Dutta Roy et al. [58] used a three dimensional 
printing process to produce scaffolds of two 
different molecular weight PLGA reinforced with 
20wt% β-TCP with or without internal channels, 
but all made porous by the incorporation of salt 
crystals. These scaffolds were implanted into the 
skulls of New Zealand White rabbits for eight 
weeks in sub-critical size defects. Both types of 
the low molecular weight implants collapsed into 
the defects with minimal new bone formation, 
however using the higher molecular weight 
polymer, the implants survived the implantation 
with some new bone formation seen in the 
channels, however the amount of new bone 
formed was less than with autograph.  
Dawson et al. [59] cultured human bone marrow 
stromal cells on scaffolds of collagen type 1 
reinforced with 70wt% carbonated HA (cHA) 
produced by Sachlos et al. [60] using a freeze 
drying process prior to subcutaneous implantation 
and compared with collagen type I scaffolds 
without cHA. The mean pore size in the 
composite scaffolds was 165µm in the composite 
scaffold and less than 64µm in the collagen. 
These pore sizes were deliberate to produce a 
biphasic material that would encourage bone 
ingrowth in the composites and cartilage 
regeneration in the collagen scaffold thus 
allowing the repair of osetocondral defects.  They 
found that the composite scaffold supported 
osteogenesis in vitro although they did have 
difficulties in differentiating between newly 
formed collagen and that of the scaffolds. The 
human bone marrow stromal cells had penetrated 
into the scaffolds with high levels of alkaline 
phosphatase activity. In vivo studies were 
performed by seeding the collagen HA scaffolds 
followed by cell culture for 72 hours and then 
implanting subcutaneously for 4 weeks or seeding 
and culturing for 48 hours and then implanting 
into a defect in the mouse femur. Subcutaneous 
implantation lead to osteoid formation and good 
integration was seen with the bony defects.  
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DISCUSSION 
While many scaffolds have been produced only a 
few have the appropriate pore sizes of both 300-
400µm across macropores and communicating 
micropores. However, the use of composite 
production techniques has allowed the increase of 
the properties by suitable processing technologies. 
The biological activities have been measured 
using three major types of tests, soaking in a 
simulated body fluid to see if an hydrated apatite 
layer is produced, indicative of the likelihood of a 
similar process occurring in vivo, cell culture to 
both ensure that the material produced is not 
cytotoxic and more importantly to show the bone 
cells be they primary cell culture or immortalised 
cell lines are up regulated again indicating an 
expected similar beneficial response in vivo and 
finally in vivo testing. Many show appropriate 
levels of porosity and bioactivity, but the major 
cause of failure of these scaffolds is the 
mechanical properties (Table 1) particularly when 
compared to the properties of natural cancellous 
bone [65]. The use of perfusion and similar 
techniques leads to improved cell distribution.  
 
CONCLUSIONS 
While a range of possible materials have been 
developed and tested, as yet none of them fulfil all 
the requirements of a bone tissue engineering 
scaffold. In general the mechanical properties are 
below those of human cancellous bone and are 
thus unable to provide even minimal mechanical 
support. However, many of these materials have 
been show to be bone bioactive using tests from 
soaking in simulated body fluid through to in vivo 
implantation, although their use in critical size 
defects has not as yet been reported. It seems 
likely that in the next few years the production of 
improved bone cell scaffolds will provide both the 
mechanical properties and required biological 
activity.  
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